	US 11,667,723 B2
	Lymphocytes-antigen presenting cells co-stimulators and uses thereof
Yangbing Zhao, Shanghai (CN); Xiaojun Liu, Shanghai (CN); Xiaodong Song, Shanghai (CN); Bin Li, Shanghai (CN); and Jintao Feng, Shanghai (CN)
Assigned to UTC Therapeutics (Shanghai) CO., LTD., Shanghai (CN)
Filed by UTC Therapeutics (Shanghai) CO., LTD., Shanghai (CN)
Filed on Aug. 21, 2022, as Appl. No. 17/821,182.
Application 17/821,182 is a continuation of application No. PCT/CN2021/112742, filed on Aug. 16, 2021.
Claims priority of application No. PCT/CN2020/109484 (WO), filed on Aug. 17, 2020.
Prior Publication US 2023/0044380 A1, Feb. 9, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 15/625 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C07K 2319/00 (2013.01); C12N 2740/15043 (2013.01)]

36 Claims

1. A polynucleotide that encodes a fusion protein comprising a first domain that activates an antigen-presenting cell (APC) and a second domain that activates an immune effector cell, wherein

(i) the first domain comprises an antibody that binds an activation receptor of the APC, or an antigen-binding fragment thereof; and

(ii) the second domain comprises a co-stimulatory receptor of the immune effector cell, or a functional fragment thereof;

wherein the first domain is an anti-CD40 scFv having an amino acid sequence selected from the group consisting of SEQ ID NOs:75, 78, 81, 87, and 90.